Severe paradoxical disease activation following alemtuzumab treatment for multiple sclerosis

被引：5
|
作者：
Brannigan, Jamie [1 ]
Jones, Joanne L. [2 ]
Stacpoole, Sybil R. L. [1 ,2 ,3 ]
机构：
[1] Univ Cambridge, Jesus Coll, Cambridge CB2 1TN, England
[2] Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Dept Neurol, Cambridge, England
[3] North West Anglia NHS Fdn Trust, Peterborough City Hosp, Dept Neurol, Peterborough, Cambs, England
来源：
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION | 2020年 / 7卷 / 05期
基金：
英国惠康基金;
关键词：
D O I：
10.1212/NXI.0000000000000799
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
A 39-year-old right-handed agricultural service engineer developed rapidly evolving severe relapsing-remitting multiple sclerosis (MS). MRI showed multiple T2 hyperintensities throughout his neuroaxis (figure, A). Several lesions showed restricted diffusion, and 2 enhanced. He received steroids for each relapse, making a full recovery (Expanded Disability Status Score [EDSS] 0).
引用
收藏
页数：3
相关论文
共 50 条
  • [31] A case of leukocytoclastic vasculitis in a multiple sclerosis patient following alemtuzumab treatment
    Edwards, Keith R.
    Lezcano, Cecilia
    Spiro, Joel
    Siuta, Jessica
    Kamath, Vineetha
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (01) : 34 - 34
  • [32] An unforeseen reality: Hemophagocytic lymphohistiocytosis following alemtuzumab treatment for a multiple sclerosis
    Osep, Anka Blagotinsek
    Brecl, Eva
    Skerget, Matevz
    Savsek, Lina
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2023, 228
  • [33] A Case of Severe Legionella Pneumonia following the Second Treatment Course of Alemtuzumab Infusion for Relapsing Remitting Multiple Sclerosis
    Spurgeon, Elizabeth
    Abbatemarco, Justin
    Rensel, Mary
    NEUROLOGY, 2018, 90
  • [34] Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort
    Cossburn, M.
    Pace, A. A.
    Jones, J.
    Ali, R.
    Ingram, G.
    Baker, K.
    Hirst, C.
    Zajicek, J.
    Scolding, N.
    Boggild, M.
    Pickersgill, T.
    Ben-Shlomo, Y.
    Coles, A.
    Robertson, N. P.
    NEUROLOGY, 2011, 77 (06) : 573 - 579
  • [35] Cladribine as rescue therapy following multiple sclerosis re-activation after Alemtuzumab
    Qadir, Shanga Hassan
    Heick, Alex
    Joensen, Hanna Poulina
    Magyari, Melinda
    Bramow, Stephan
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1055 - 1056
  • [36] B CELL DEPLETION THERAPY RESULTING IN SUSTAINED REMISSION OF SEVERE AUTOIMMUNE COMPLICATIONS FOLLOWING ALEMTUZUMAB TREATMENT OF MULTIPLE SCLEROSIS
    Massey, Jennifer
    Sutton, Ian
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2019, 90 (E7):
  • [37] Alopecia totalis following alemtuzumab treatment in relapsing-remitting multiple sclerosis
    Zimmermann, J.
    Buhl, T.
    Mueller, M.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 382 - 382
  • [38] Thyroid autoimmunity following alemtuzumab treatment in multiple sclerosis patients: a prospective study
    Kazakou, Paraskevi
    Tzanetakos, Dimitrios
    Vakrakou, Aigli G.
    Tzartos, John S.
    Evangelopoulos, Maria-Eleptheria
    Anagnostouli, Maria
    Stathopoulos, Panos
    Kassi, Georgia N.
    Stefanis, Leonidas
    Kilidireas, Constantinos
    Zapanti, Evangelia
    CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (06) : 2885 - 2894
  • [39] Acute respiratory distress syndrome following treatment with alemtuzumab for relapsing multiple sclerosis
    Pace, A.
    Jackson, F.
    Lusher, W.
    Mihalova, T.
    Sharaf, N.
    Rog, D.
    Talbot, P.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 318 - 319
  • [40] Thyroid autoimmunity following alemtuzumab treatment in multiple sclerosis patients: a prospective study
    Paraskevi Kazakou
    Dimitrios Tzanetakos
    Aigli G. Vakrakou
    John S. Tzartos
    Μaria-Eleptheria Evangelopoulos
    Maria Anagnostouli
    Panos Stathopoulos
    Georgia N. Kassi
    Leonidas Stefanis
    Constantinos Kilidireas
    Evangelia Zapanti
    Clinical and Experimental Medicine, 2023, 23 : 2885 - 2894
12345